News & Events
Update on Rotavirus Vaccines
In March 2010, FDA became aware of the presence PCV1 in Rotarix and DNA from PCV1 and PCV2 in RotaTeq. These viruses are not known to cause any infection or illness in people. Based on a careful review of a variety of scientific information, FDA has determined it is appropriate for clinicians and public health professionals in the United States to use these vaccines. All available evidence supports the safety and effectiveness of Rotarix and RotaTeq, which have been extensively studied, both before and after approval.
This webpage provides additional background information, including questions and answers for patients and providers.
Topics on this page:
- News Updates
- About Rotavirus, PCV, and the Rotavirus Vaccines
- For Parents and Caregivers
- For Health Professionals
- Update on Rotavirus Vaccine
- Update on Recommendations for the Use of Rotavirus Vaccines
- Early Communication on Rotarix Vaccine
- Detection of DNA from PCV1 in Rotarix
- FDA Actions
- FDA News Release: Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
- Transcript for FDA's Media Briefing on Rotarix Vaccine
- Video: Update on Rotarix Vaccine [6:24 min]
About Rotavirus, PCV, and the Rotavirus Vaccines:
- Background on Viral Vaccine Development
- Background on Rotavirus
- Rotavirus Infection (Centers for Disease Control and Prevention)
- Background on Rotavirus Vaccines
- Background on PCV
- Information for Parents and Caregivers
- Rotavirus Vaccination (Centers for Disease Control and Prevention)
- Information for Healthcare Providers and Public Health Professionals
- Bad Bugs Book: Rotavirus
- Rotarix
- RotaTeq